Recap: Leap Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Leap Therapeutics (NASDAQ:LPTX) reported Q3 earnings with an EPS of $-0.51, beating estimates by 12.07% but with no change in revenue from the same period last year. Last quarter's EPS miss was followed by a 5.83% share price increase the next day.
November 13, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leap Therapeutics reported a better-than-expected Q3 EPS, beating estimates by 12.07%, but showed no revenue growth from the same period last year.
Beating earnings estimates typically has a positive effect on stock price, as seen with LPTX's last quarter performance where the stock increased by 5.83% following an EPS miss. However, the lack of revenue growth may temper investor enthusiasm, leading to a mixed reaction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100